04.30.21

Ocular Therapeutix to Present Preclinical and Clinical Data at ARVO

Source: Ocular Therapeutix

Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. With the ARVO 2021 Annual Meeting being moved to a virtual format, video-recorded presentations are scheduled to become available online at ARVOLearn on May 1, 2021.

“We are pleased to be presenting data on our preclinical and clinical programs at this year’s annual meeting, including updated data on two of our key programs, OTX-TKI for the treatment of wet AMD and OTX-TIC for the reduction of IOP in patients with primary open-angle glaucoma or ocular hypertension,” Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, said in a company news release. “The progress we are making in these two programs is exciting as we look to advance each into phase 2 clinical trials. Our hydrogel platform continues to offer patients and physicians a potential novel, hands-free option to address both front and back-of-the-eye diseases. We look forward to the continued progress of these programs while we continue expanding the capabilities of our diverse platform.”

Presentations at ARVO:

  • Title: Safety and Efficacy of Topical, Transzonular, and Intracanalicular Corticosteroids for the Prevention of Postoperative Inflammation after Cataract Surgery
    Session Title: Cataract Surgery/Epidemiology
    Session Date/Times: May 2, 2021 from 11:15 AM to 1:00 PM EDT
    Presenter: Dr. Amy Lu
  • Title: Phase 1 Study of an Intracameral Travoprost Hydrogel-based Implant for the Treatment of POAG and Ocular Hypertension
    Session Title: Pharmacological intervention and cellular mechanisms
    Session Date/Times: May 3, 2021 from 11:15 AM to 1:00 PM EDT
    Presenter: Dr. Damien Goldberg
  • Title: Incidence of Endophthalmitis Following Routine or Complex Cataract Surgery in Practices With and Without Access to Hydrogel Sealant: Retrospective Study Using the IRIS Registry
    Session Title: Healthcare Delivery and Quality of Care
    Session Date/Times: May 5, 2021 from 9:00 AM to 10:45 AM EDT
    Presenter: Dr. Michael H Goldstein
  • Title: Phase 1 Study of an Intravitreal Axitinib Hydrogel-based Implant for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
    Session Title: AMD and retinal physiology
    Session Date/Times: May 5, 2021 from 2:45 PM to 4:30 PM EDT
    Presenter: Dr. James Wong
  • Title: Ocular Pharmacokinetics of OTX-DED, a Sustained-release Intracanalicular Insert Delivering Dexamethasone, in a Canine Model
    Session Title: Dry Eye and Tear film
    Session Date/Times: May 5, 2021 from 2:45 PM to 4:30 PM EDT
    Presenter: Charles Blizzard
  • Title: Pharmacokinetics of OTX-CSI, a Cyclosporine Intracanalicular Insert, in Surgically Induced Dry Eye Beagle Dogs
    Session Title: Cornea, cytokines, anti-inflammatory
    Session Date/Times: May 7, 2021 from 2:15 PM to 4:00 PM EDT
    Presenter: Andrew Vanslette
  • Title: Safety of an Intracanalicular Dexamethasone Insert for the Treatment of Allergic Conjunctivitis: Pooled Post-hoc Analysis of Four Studies
    Session Title: Cornea, cytokines, anti-inflammatory
    Session Date/Times: May 7, 2021 from 2:15 PM to 4:00 PM EDT
    Presenter: Dr. John Meyer

The online presentations are expected to be hosted in the Media library catalog within ARVOLearn.

 

Related Content